CV9104 / CureVac - LARVOL DELTA

Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2017) - "Safety and immune responses to the predecessor therapy CV9103 encoding 4 of the antigens have been described previously. CV9104 did not improve OS compared to placebo. Additional clinical outcomes and analyses of cellular and humoral immune responses will be presented and impact on further development will be discussed."

Clinical • P1/2 data • Prostate Cancer

Results of an open label randomized phase II trial of CV9104, an mRNA-based multivalent cancer immunotherapy in patients (pts) with intermediate or high risk localized prostate cancer (PC) undergoing radical prostatectomy (RPE) (ESMO 2017) - "CV9104 was well tolerated using either nflD or clD injection, with a safety profile similar to other previous mRNA-based cancer immunotherapies. Cellular and humoral immune responses including responses per antigen and additional biomarker results will be presented."

Adverse events • P2 data • Prostate Cancer

Emerging therapeutic targets for patients with advanced prostate cancer. (PubMed, Cancer Treat Rev) - "Further, we outline current approaches for novel prostate cancer vaccines such as DCVAC/PCa, PROSTVAC-V/F, MVI-816, CV9104, and PF-06753512. This wide spectrum of potential treatment strategies holds promise for additional improvements in the treatment of patients with CRPC, as these novel agents are aimed at targets known to be associated with growth and malignant progression of prostate cancer. If primary study endpoints are met, findings from ongoing phase III trials of well-tolerated and active combinations may provide new effective treatment options for advanced prostate cancer and thereby contribute to enhanced disease control in CRPC patients."

Clinical • Journal • Review